Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.
Barriers still stand in the way of making treatment available to all who need it.
Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
The early cancer is detected, the easier it is to treat.
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
Blue Faery’s “Love Your Liver” 28-day video campaign raises awareness of liver cancer and overall liver health.
Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.
Areas with lower population density have not seen the same slowdown as urban areas.
Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.
The blood-borne virus, which can lead to cirrhosis and liver cancer, remains a major global health threat.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.